Skip to content

Calculus exits Mologic – generating up to a 3.6x return for investors

Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Calculus successfully exit Mologic by sale to new philanthropic entity Global Access Health London 19 July 2021: Calculus Capital (“Calculus”), pioneers of the tax efficient investment … Continued

Calculus VCT Annual General Meeting 2021

The Annual General Meeting (AGM) of Calculus VCT plc (the “Company”) will be held at 12.30pm on 8 July 2021. The AGM is an important event in the Company’s corporate calendar, providing an opportunity for shareholders to meet the board and put questions to the directors and the investment manager, as well as enabling shareholders … Continued

Calculus invests in Spectral MD

Calculus VCT has invested £0.5m into Spectral MD through an oversubscribed inital public offering onto AIM, on Tuesday 22 June. The Dallas-based firm, which is building notable presence in the UK as part of its product launch effort, produces predictive analytics, proprietary AI algorithms and imaging systems to assist with medical treatment. Spectral MD’s technology, … Continued

Calculus invests in Arecor following successful IPO

Arecor announced its admission to trading on AIM, a market operated by London Stock Exchange, on 3 June 2021. Admission follows a successful oversubscribed placing by Panmure Gordon, raising gross proceeds of £20 million at a price of 226 pence per share. On Admission the Company will have a market capitalisation of approximately £62.5 million. … Continued

Calculus Exits Sports Tour Operator inspiresport

inspiresport is the industry leading sports development tour operator, offering unrivaled access to world class clubs, coaches, and facilities to take young players of all abilities on extraordinary sporting journeys. The company has been acquired by Portman Travel Group, which is expanding into the sports travel market, providing an exit event for Calculus investors. Calculus, … Continued

Arecor granted key US patent

Cambridge, UK., 13 May 2021 – Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the grant by the United States Patent and Trademark Office of U.S. Utility Patent No. 10,925,965 B2, a patent that contributes to the Company’s global patent portfolio underpinning its ArestatTM technology … Continued

Calculus invests in Invizius

The University of Edinburgh spin-out is developing potentially lifesaving products that help reduce complications and high death rates amongst dialysis patients. Incoming institutional investor Calculus Capital has participated in a funding round with existing investors Downing Ventures and Mercia, alongside Solvay Ventures, Scottish Enterprise and Old College Capital Glasgow, Scotland, May 6th, 2021 – Invizius … Continued

Blu Wireless accelerates growth with opening of new US business entity

Business expansion and appointment of local team will enable Blu Wireless to accelerate growth in the defence, public safety, and transport sectors, providing enhanced customer service in North America. Blu Wireless, the leader in 5G mmWave networking equipment, has today announced the expansion into the United States with the launch of Blu Wireless Technology Inc. … Continued

C4X signs exclusive worldwide licensing agreement with Sanofi worth up to €414 million

The licensing agreement, which C4X will receive an upfront payment of €7 million from, is for their oral pre-clinical IL-17A inhibitor programme. 12 April 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that its subsidiary, C4X Discovery Limited (“C4XD”, “C4X Discovery” or the “Company”), has signed an exclusive worldwide licensing agreement with … Continued

Arecor receives £2.8 million grant award from Innovate UK

Coveted award for Phase II clinical development of lead product, AT247, its next generation ultra-rapid acting Insulin Cambridge, UK., 31st Mar 2021: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has been awarded a £2.8 million grant from Innovate UK to support the … Continued

Calculus Capital delivers 6x return with ActiveOps listing

Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Calculus Capital portfolio company ActiveOps has completed a successful Initial Public Offering on the Alternative Investment Market, generating an impressive 6x return for Calculus EIS investors. … Continued

Calculus Capital invests in Axol Bioscience following merger with Censo Biotechnologies

Biotech sector-leaders combine tools, talent, and technologies to drive life science discovery forward Merger accompanied by £3.8million ($5.3m USD) investment across existing shareholders and new investors, which will be used to fund recruitment and growth of the business Axol Bioscience Ltd, an established provider of stem cells produced from reprogrammed human blood and tissue cells, … Continued

Open Orphan wins contract with Oxford Biotherapeutics

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its subsidiary Venn Life Sciences (“Venn”) has been awarded a contract for a study with Oxford BioTherapeutics, a clinical stage oncology company with a pipeline of immune-oncology and antibody-drug conjugate-based therapies. This … Continued

Celebrating Women in Leadership

Today, on International Women’s Day 2021, we join companies around the globe celebrating the social, economic, cultural, and political achievements of women. International Women’s Day #IWD2021 is an annual reminder to not only recognise and champion greater female representation but also to accelerate gender parity. For this year’s theme #ChooseToChallenge, we believe Calculus leads by … Continued

Support for the creative industries

The creative sector makes a remarkable contribution to the UK economy It is integral to the UK’s economic and social regeneration £400m budget bonus to support the arts British stars dominated at Sunday evening’s Golden Globes virtual awards ceremony with The Crown taking several awards and Sacha Baron Cohen and John Boyega also scooping top … Continued

Calculus invests in eConsult

eConsult Health is the leading online consultation provider to the NHS for primary care With considerable growth over the last year the platform is now live in over 3,200 NHS GP practices and gives millions of patients access to their own GP online. The funding round will be used to accelerate growth in primary care … Continued

Naomi Watts to headline new film produced by Maven Screen Media

Naomi Watts is set to headline “Infinite Storm,” the highly anticipated film from Polish director Malgorzata Szumowska. “Infinite Storm” is being produced by Maven Screen Media’s Celine Rattray, Trudie Styler and Jenny Halper with Naomi Watts for JamTart Productions, as well as Peter and Michael Sobiloff. Calculus invested in Maven Screen Media in August 2020. Specifically, Maven … Continued

Surrey trust pilots the NHS’ first-of-its-kind demand-led rostering solution with Rotageek

Surrey-based Ashford and St Peter’s Hospitals NHS Foundation Trust, one of the UK’s foremost Trusts, is piloting a demand-led rostering solution with Rotageek and Locum’s Nest, who create software connecting healthcare professionals to flexible work. Together they will test the NHS’ first-of-its-kind demand-led rostering. The solution links scheduling and locums in an integrated network that … Continued

An Investment Outlook: Looking forward to 2021

Richard Moore – Co head of Investments Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. 2020 impacted businesses both large and small. Covid-19 and government mandated lockdowns created a very uncertain economic outlook and … Continued

Oxford BioTherapeutics establishes research collaboration with global cell therapy leader, Kite

Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies and Kite, a Gilead Company, have announced that they have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications. Through this collaboration, OBT will validate five … Continued

Arecor’s partner Inhibrx to license first formulation

Arecor has announced that partner Inhibrx Inc. is to license a novel enhanced formulation of its proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat™. This is the first license under a multi-product development agreement between two companies with the new formulation developed using Arestat, Arecor’s patented reformulation platform. INBRX-101 is a treatment for … Continued

Calculus VCT plc Annual General Meeting 2020

The Annual General Meeting (AGM) of Calculus VCT plc (the “Company”) will be held at 11.30am on 3 July 2020. The AGM is an important event in the Company’s corporate calendar, providing an opportunity for shareholders to meet the board and put questions to the directors and the investment manager, as well as enabling shareholders … Continued